AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16351554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction (measured using a modified version of the CAHPS survey)
Number of subjects: 542
Study 11522879 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 10
Study 11522879 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (BD)
Number of subjects: 10
Study 9565804 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - 150 mg/kg bolus in 250 ml of 5% dextrose followed by continuous infusion of 12 mg/kg per hour in 500 ml of 5% dextrose over 24 hours for a minimum of 3 days up to a maximum of 5 days.
Number of subjects: 50
Study 9565804 — intervention group
Group type: COMPARATOR
Intervention: Placebo - equal volume of placebo administered for the same duration as NAC.
Number of subjects: 50
Study 21207908 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (n = 77)
Number of subjects: 231
Study 21207908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study 3357653 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) patch 50 micrograms/day
Number of subjects: 17
Study 3357653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29954359 — intervention group
Group type: EXPERIMENTAL
Intervention: BF Spiromax
Number of subjects: 493
Study 29954359 — intervention group
Group type: COMPARATOR
Intervention: BF Turbuhaler
Number of subjects: 493
Study 26201713 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg thrice a day)
Number of subjects: 112
Study 26201713 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (30-120 ml/day)
Number of subjects: 112
Study 23456311 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps to Respect: A Bullying Prevention Program (STR)
Number of subjects: 1424
Study 21748313 — intervention group
Group type: COMPARATOR
Intervention: Oral fluids only
Number of subjects: 293
Study 21748313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer lactate at 125 ml/h
Number of subjects: 293
Study 21748313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer lactate at 250 ml/h
Number of subjects: 293
Study 20731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reminder use among patients with unhealthy drinking (descriptive cohort)
Number of subjects: 22863
Study 20731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented brief intervention among patients with clinical-reminder use
Number of subjects: 22863
Study 20731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to clinical reminder and resolution of unhealthy drinking (outcomes cohort)
Number of subjects: 22863
Study 17634541 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of IFN gamma receptor
Number of subjects: 339
Study 17634541 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete loss of IFN gamma receptor
Number of subjects: 339
Study 16129986 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Number of subjects: 50
Study 16129986 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 50
Study 12325095 — intervention group
Group type: EXPERIMENTAL
Intervention: Large trials
Number of subjects: 0
Study 10917002 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mEq/l dialysate calcium (DCa)
Number of subjects: 20
Study 10917002 — intervention group
Group type: COMPARATOR
Intervention: 3 mEq/l dialysate calcium (DCa)
Number of subjects: 20
Study 9037846 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 10 weeks
Number of subjects: 40
Study 9037846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study 2056888 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride (150 mg po/die)
Number of subjects: 30
Study 2056888 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic sulpiride (300 mg po/die)
Number of subjects: 30
Study 6318655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human interferon alpha A
Number of subjects: 0
Study 6318655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30819098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria intervention for 6 months
Number of subjects: 366
Study 30819098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria and behavioral intervention for 6 months
Number of subjects: 366
Study 30819098 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 366
Study 29931092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 572
Study 29931092 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 572
Study 27094556 — intervention group
Group type: EXPERIMENTAL
Intervention: brush‐plus‐rinse treatment
Number of subjects: 91
Study 27094556 — intervention group
Group type: COMPARATOR
Intervention: brush‐alone treatment
Number of subjects: 91
Study 27094556 — intervention group
Group type: COMPARATOR
Intervention: dental scaling regimen
Number of subjects: 91
Study 24138335 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 80
Study 24138335 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 22555430 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 21
Study 22555430 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 19602539 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h group‐based structured education program with personalized steps‐per‐day goals and pedometers
Number of subjects: 87
Study 19602539 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h group‐based structured education program with generic time‐based goals
Number of subjects: 87
Study 19602539 — intervention group
Group type: COMPARATOR
Intervention: Brief information leaflet (control condition)
Number of subjects: 87
Study 17848748 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid (4 mg, iv, every 28 d)
Number of subjects: 94
Study 17848748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 94
Study 24125844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diffuse fibrosis (T1 < 470 ms)
Number of subjects: 37
Study 24125844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without diffuse fibrosis (T1 >= 470 ms)
Number of subjects: 37
Study 24125844 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 24125844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diffuse fibrosis
Number of subjects: 37
Study 24125844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without diffuse fibrosis
Number of subjects: 37
Study 24125844 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with T1 time
Number of subjects: 37
Study 11194183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% procyanidin B-2 tonic
Number of subjects: 29
Study 11194183 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 29
Study 9061712 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification with a low calorie diet
Number of subjects: 158
Study 9061712 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification with a very low calorie diet
Number of subjects: 158
Study 9061712 — intervention group
Group type: COMPARATOR
Intervention: Behavior modification (control group not specified)
Number of subjects: 158
Study 9061712 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity assessment using the Bergman minimal model
Number of subjects: 158
Study 9061712 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity at 12 months
Number of subjects: 158
Study 8141692 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg twice daily)
Number of subjects: 0
Study 8141692 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once daily)
Number of subjects: 0
Study 3533455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (100 mg)
Number of subjects: 9
Study 3533455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (0.4 mg)
Number of subjects: 9
Study 3533455 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline and diprophylline
Number of subjects: 9
Study 3533455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2484920 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroquinidine (900 mg/day)
Number of subjects: 14
Study 2484920 — intervention group
Group type: EXPERIMENTAL
Intervention: quinidine (1,650 mg/day)
Number of subjects: 14
Study 2484920 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroquinidine
Number of subjects: 14
Study 31952034 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for municipal physical rehabilitation (REHAB)
Number of subjects: 146
Study 31952034 — intervention group
Group type: COMPARATOR
Intervention: No referral to any postoperative rehabilitation (HOME)
Number of subjects: 146
Study 31889148 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted hepatitis B vaccine
Number of subjects: 123
Study 31889148 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza vaccine (ATIV)
Number of subjects: 123
Study 31889148 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted TIV
Number of subjects: 123
Study 31889148 — intervention group
Group type: EXPERIMENTAL
Intervention: Live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines
Number of subjects: 123
Study 29275580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: dose-dense TEC× 4 every 2 weeks with G-CSF
Number of subjects: 168
Study 29275580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: sequential EC× 4 (dose-dense)-T × 4 every 2 weeks
Number of subjects: 168
Study 29275580 — intervention group
Group type: COMPARATOR
Intervention: Group A: concurrent TEC× 4 every 3 weeks
Number of subjects: 168
Study 29275580 — intervention group
Group type: COMPARATOR
Intervention: Group B: sequential EC× 4-T × 4 every 3 weeks
Number of subjects: 168
Study 25185471 — intervention group
Group type: EXPERIMENTAL
Intervention: Charge awareness video (n = 49)
Number of subjects: 100
Study 25185471 — intervention group
Group type: COMPARATOR
Intervention: No charge awareness video (n = 51)
Number of subjects: 100
Study 23274145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin test formulation (generic) 20 mg per day for 8 weeks
Number of subjects: 298
Study 23274145 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin reference formulation (original) 20 mg per day for 8 weeks
Number of subjects: 298
Study 23274145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin test formulation
Number of subjects: 298
Study 23274145 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin reference formulation
Number of subjects: 298
Study 20812240 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior plus nutrition intervention and nutrition education alone (Clinical Trial Group)
Number of subjects: 67
Study 20812240 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Comparison Sample)
Number of subjects: 67
Study 18471517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Whipple procedure
Number of subjects: 0
Study 18471517 — intervention group
Group type: COMPARATOR
Intervention: Extended drainage procedure (Frey)
Number of subjects: 0
Study 16504484 — intervention group
Group type: EXPERIMENTAL
Intervention: Group housing (Evolving Consumer Households)
Number of subjects: 112
Study 16504484 — intervention group
Group type: COMPARATOR
Intervention: Independent apartments
Number of subjects: 112
Study 16504484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both housing conditions
Number of subjects: 112
Study 15281283 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer drugs (33% off label use)
Number of subjects: 396
Study 10667492 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg in four divided doses on days 1, 2, 3, and 6)
Number of subjects: 39
Study 10667492 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 39
Study 10667492 — intervention group
Group type: COMPARATOR
Intervention: Control (human albumin)
Number of subjects: 39
Study 10667492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 9059098 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger
Number of subjects: 60
Study 9059098 — intervention group
Group type: COMPARATOR
Intervention: No heat and moisture exchanger
Number of subjects: 60
Study 8364347 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg S(+) OXP daily
Number of subjects: 20
Study 8364347 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg R(‐) OXP daily
Number of subjects: 20
Study 8364347 — intervention group
Group type: COMPARATOR
Intervention: 75 mg S(+) OXP single dose (normal controls)
Number of subjects: 20
Study 8364347 — intervention group
Group type: COMPARATOR
Intervention: 75 mg R(‐) OXP single dose (normal controls)
Number of subjects: 20
Study 3090864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (low to moderate doses)
Number of subjects: 100
Study 3090864 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (10 mg tid, active placebo)
Number of subjects: 100
Study 3090864 — intervention group
Group type: COMPARATOR
Intervention: Non-medication group
Number of subjects: 100
Study 31763959 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III malocclusion group
Number of subjects: 648
Study 31763959 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 648
Study 31763959 — intervention group
Group type: COMPARATOR
Intervention: Different malocclusion groups
Number of subjects: 648
Study 31763959 — intervention group
Group type: EXPERIMENTAL
Intervention: Age values
Number of subjects: 648
Study 30952575 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300) managed by nurse-assisted patients
Number of subjects: 458
Study 30952575 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 300 U/mL (Gla-300) managed by physicians
Number of subjects: 458
Study 28446644 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1969
Study 28446644 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1969
Study 28446644 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (CAS and CEA combined)
Number of subjects: 1969
Study 28446644 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (BMI 25-<30)
Number of subjects: 1969
Study 26300710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (1 ng/kg)
Number of subjects: 12
Study 26300710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23020760 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 L beetroot (BR) juice
Number of subjects: 10
Study 23020760 — intervention group
Group type: COMPARATOR
Intervention: 0.5 L placebo (PLA) drink with blackcurrant juice
Number of subjects: 10
Study 21698578 — intervention group
Group type: EXPERIMENTAL
Intervention: Short rotators intact
Number of subjects: 68
Study 21698578 — intervention group
Group type: COMPARATOR
Intervention: Short rotators released
Number of subjects: 68
Study 18082668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 158
Study 18082668 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg
Number of subjects: 158
Study 16293396 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week combined treatment approach using vocal function exercises (VFEs) and vocal hygiene (VH) education
Number of subjects: 20
Study 16293396 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 20
Study 12898761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection with 1.0 ml of 2% chitosan
Number of subjects: 30
Study 12898761 — intervention group
Group type: COMPARATOR
Intervention: Control group with 12.5 mg of prednisolone
Number of subjects: 30
Study 11303537 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 3 ml 1% l-menthol solution
Number of subjects: 64
Study 11303537 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation of 3 ml 0.05% l-menthol
Number of subjects: 64
Study 9302365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 43
Study 9302365 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar irradiation
Number of subjects: 43
Study 9302365 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 43
Study 8362837 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloscreen Self-Test
Number of subjects: 283
Study 8362837 — intervention group
Group type: COMPARATOR
Intervention: Guaiac cards
Number of subjects: 283
Study 8362837 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloscreen Self-Test (VA clinic)
Number of subjects: 283
Study 8362837 — intervention group
Group type: COMPARATOR
Intervention: Guaiac cards (VA clinic)
Number of subjects: 283
Study 2426514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 0.5 ng/kg X min
Number of subjects: 6
Study 2426514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 1.0 ng/kg X min
Number of subjects: 6
Study 2426514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 2.0 ng/kg X min
Number of subjects: 6
Study 2426514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 3.0 ng/kg X min
Number of subjects: 6
Study 2426514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29658504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nooclerin (deanoli aceglumas)
Number of subjects: 90
Study 29658504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 28513852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg orally before thrombolytic therapy)
Number of subjects: 98
Study 28513852 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protocol for treatment of MI)
Number of subjects: 98
Study 26701110 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 899
Study 26701110 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 899
Study 26701110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 899
Study 26701110 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 899
Study 23394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Algisyl‐LVR™+CABG
Number of subjects: 3
Study 21410296 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575
Number of subjects: 268
Study 21410296 — intervention group
Group type: COMPARATOR
Intervention: Epogen®
Number of subjects: 268
Study 21410296 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575-TT
Number of subjects: 268
Study 21410296 — intervention group
Group type: EXPERIMENTAL
Intervention: Erypo®/Eprex®
Number of subjects: 268
Study 18205579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ankle-pressure graduated-compression tights (GCTs)
Number of subjects: 47
Study 16341712 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-distraction (FD)
Number of subjects: 235
Study 16341712 — intervention group
Group type: COMPARATOR
Intervention: Active trunk exercise protocol (ATEP)
Number of subjects: 235
Study 12732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 45
Study 12732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 45
Study 10936631 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 181
Study 10936631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 181
Study 10936631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatment (IPT or NT)
Number of subjects: 181
Study 10936631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 181
Study 9065248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-propofol
Number of subjects: 18
Study 9065248 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-propofol
Number of subjects: 18
Study 2052740 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release hydrogel polymer prostaglandin E2 pessary (0.6 mg PGE2 per hour)
Number of subjects: 0
Study 6192652 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor blockade alone
Number of subjects: 20
Study 6192652 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor blockade in combination with H2 receptor blockade
Number of subjects: 20
Study 6192652 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor blockade alone
Number of subjects: 20
Study 31906882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting disease-specific survival (DSS) rates
Number of subjects: 5764
Study 31283830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 25
Study 31283830 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 25
Study 27977472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and hydrochlorothiazide
Number of subjects: 793
Study 27977472 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine and metoprolol
Number of subjects: 793
Study 25847112 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antidepressants (mainly selective serotonin reuptake inhibitors)
Number of subjects: 138704
Study 25847112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 138704
Study 23551394 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers training
Number of subjects: 57
Study 20651608 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E) - 90 maximal isokinetic eccentric-concentric knee extensor contractions on each of 3 consecutive days followed by 1-day rest, then on 4 more consecutive days.
Number of subjects: 17
Study 20651608 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E)
Number of subjects: 17